Bon Natural Life Ltd
NASDAQ:BON

Watchlist Manager
Bon Natural Life Ltd Logo
Bon Natural Life Ltd
NASDAQ:BON
Watchlist
Price: 1.69 USD -0.59% Market Closed
Market Cap: 11.8m USD

Bon Natural Life Ltd
Investor Relations

Bon Natural Life Ltd. engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants which are widely used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company is headquartered in Xi'An, Shaanxi and currently employs 93 full-time employees. The company went IPO on 2021-06-24. The firm's product categories include fragrance compounds, health supplements (natural, functional active ingredients for powder drinks) and bioactive food ingredients. Fragrance compounds product category includes clary sage extract products. Bioactive food ingredients include stachyose, milk thistle extracts, apple extracts, phloretin and pomegranate extract products. The Company’s products are applied in the functional food, personal care, cosmetic and pharmaceutical industries.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q4 2022
Call Date
Feb 10, 2023
AI Summary
Q4 2022

Revenue Growth: Bon Natural Life reported 2022 revenue of $29.9 million, up 17.3% year-over-year, driven by higher average selling prices and increased volumes in key categories.

Profitability: Net income rose 35.4% to $6.2 million and gross profit increased 32.5% to $9.4 million, reflecting improved sales mix and pricing.

Product & Capacity Expansion: The company is completing its Yumen Plant, expecting a 200% increase in production capacity and up to 150% revenue growth from the new facility.

New Products: Bon introduced innovative products like FeatherPure for female care and a broccoli-based probiotic drink, aiming to tap into new growth areas.

Overseas Sales: Overseas revenue dropped due to supply chain disruptions and port congestion, but management expects a rebound in 2023.

Accounts Receivable: The company saw a rise in receivables but reported no payment issues or bad debt as of January 2023.

Key Financials
Revenue
$29.9 million
Gross Profit
$9.4 million
Net Income
$6.2 million
Diluted Earnings Per Share
$0.74
Government Subsidies (Other Operating Income)
$1.3 million
Accounts Receivable
over $6 million
Revenue from Fragrance Compounds
$13.7 million
Revenue from Health Supplements
$7.1 million
Revenue from Bioactive Ingredients
$9.1 million
Domestic China Revenue
$28.8 million
Overseas Revenue
$1.2 million
Other Earnings Calls

Management

Mr. Yongwei Hu
Chairman & CEO
No Bio Available
Mr. Wang L. Lee
Chief Financial Officer
No Bio Available
Ms. Yingchun Xue
Chief Operating Officer
No Bio Available
Mr. Jianli Liu
CTO & Chief Scientist
No Bio Available
Ms. Wenjuan Chen
Chief Marketing Officer
No Bio Available

Contacts

Address
SHAANXI
Xi'an
C601, Gazelle Valley, No.69 Jinye Rd., Xi'An-Tech Zone
Contacts
+862988318908.0
www.bnlus.com